SAN DIEGO, CA — November 11, 2025 — Leads & Copy — Quantumzyme Corp. (OTCQB: QTZM) announced the expansion of its AI-powered enzyme design platform to target high-volume Active Pharmaceutical Ingredients (APIs) beyond ibuprofen, marking a major advancement in green pharmaceutical manufacturing.
Building on its validated enzymatic process for green ibuprofen synthesis, Quantumzyme’s expanded program leverages its enzyme families, machine learning predictive models, and in silico design workflows to develop sustainable pathways for APIs with significant global environmental impact.
Quantumzyme’s enzyme engineering platform integrates advanced AI-driven computational modeling, in silico directed evolution, mechanistic simulation, and high-throughput validation to deliver optimized biocatalysts, replacing traditional energy-intensive chemical reaction steps.
The expanded R&D pipeline includes multiple high-volume APIs, featuring chiral intermediates like phenylephrine and related compounds accessible via ketoreductases, widely used in the global generics sector. This highlights the scalability of Quantumzyme’s digital biology architecture and its ability to rapidly adapt and redeploy enzyme systems across diverse synthesis targets.
Quantumzyme CEO Naveen Kulkarni stated that the global API market is projected to exceed $300 billion USD by 2030, with generic drugs representing the majority of production volume. Kulkarni also stated that much of this manufacturing occurs overseas using legacy chemistries that generate heavy waste streams and carry high solvent and carbon intensity. Quantumzyme’s goal is to develop a sustainable and eco-friendly approach.
Quantumzyme’s biocatalysis-first approach delivers reduced chemical waste and solvent usage, a lower carbon footprint, elimination of toxic reagents, and improved cost and yield efficiency. The company’s platform supports domestic API manufacturing and aligns with U.S. supply chain resilience and sustainability goals.
Kulkarni added that Quantumzyme’s vision is to redefine chemical manufacturing through sustainable innovation, advancing greener chemistry, supporting supply chain resiliency, and moving closer to a future where enzyme-driven production becomes the industry standard for high-volume APIs by extending their enzyme engineering platform beyond ibuprofen.
For more information, visit www.quantumzymecorp.com and the Company’s profile at www.otcmarkets.com/stock/QTZM.
Naveen Kulkarni, Chief Executive Officer, Quantumzyme Corp. can be reached at +1 (858) 203-0312 or info@quantumzymecorp.com
Source: Quantumzyme Corp.
